Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label long-term safety and efficacy study of olokizumab (CDP6038) in rheumatoid arthritis patients who completed RA0056
2010-022224-77Phase 2Terminated
- Sponsor
- UCB
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olokizumab in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoint: Primary safety variables. Started Dec 2010; status: terminated.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022224-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022224-77.